Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Open Access
- 15 January 2013
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 6 (1), 85-107
- https://doi.org/10.3390/ph6010085
Abstract
RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.Keywords
This publication has 134 references indexed in Scilit:
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- Barriers to Non-Viral Vector-Mediated Gene Delivery in the Nervous SystemPharmaceutical Research, 2011
- RNAi and small interfering RNAs in human disease therapeutic applicationsTrends in Biotechnology, 2010
- Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug deliveryOral Oncology, 2010
- Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian CellsSmall, 2010
- Polyethylenimine/small interfering RNA‐mediated knockdown of vascular endothelial growth factor in vivo exerts anti‐tumor effects synergistically with BevacizumabThe Journal of Gene Medicine, 2010
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- Methotrexate delivery via folate targeted dendrimer‐based nanotherapeutic platformWIREs Nanomedicine and Nanobiotechnology, 2009
- Engineered polymers for advanced drug deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008